|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0033607,
umls-concept:C0040808,
umls-concept:C0132326,
umls-concept:C0205195,
umls-concept:C0332256,
umls-concept:C0549178,
umls-concept:C0663655,
umls-concept:C0674428,
umls-concept:C1280519,
umls-concept:C1511253,
umls-concept:C1704419
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2011-7-12
|
|
pubmed:abstractText |
To compare virological effectiveness in patients who continued on a virologically successful first-line boosted protease inhibitor (PI)-containing combination antiretroviral therapy (cART) regimen or who switched to a PI-free cART including efavirenz, nevirapine or abacavir.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1460-2091
|
|
pubmed:author |
pubmed-author:AbgrallSS,
pubmed-author:BommenelTT,
pubmed-author:CostagliolaDD,
pubmed-author:FHDH-ANRS CO4,
pubmed-author:GilquinJJ,
pubmed-author:KatlamaCC,
pubmed-author:LascauxA SAS,
pubmed-author:LaunayOO,
pubmed-author:MahamatAA,
pubmed-author:MartinetLL,
pubmed-author:MeynardJ LJL,
pubmed-author:PradierCC,
pubmed-author:RouveixEE,
pubmed-author:SimonAA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1869-77
|
|
pubmed:meshHeading |
pubmed-meshheading:21636583-Adult,
pubmed-meshheading:21636583-Anti-HIV Agents,
pubmed-meshheading:21636583-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:21636583-Benzoxazines,
pubmed-meshheading:21636583-Cohort Studies,
pubmed-meshheading:21636583-Dideoxynucleosides,
pubmed-meshheading:21636583-Female,
pubmed-meshheading:21636583-HIV,
pubmed-meshheading:21636583-HIV Infections,
pubmed-meshheading:21636583-HIV Protease Inhibitors,
pubmed-meshheading:21636583-Humans,
pubmed-meshheading:21636583-Male,
pubmed-meshheading:21636583-Nevirapine,
pubmed-meshheading:21636583-Prospective Studies,
pubmed-meshheading:21636583-Treatment Outcome,
pubmed-meshheading:21636583-Viral Load
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
|
|
pubmed:affiliation |
INSERM U943, Paris F-75013, France.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
